A rubric works only if you write it down before you look at the field. So that is the order here: state the criteria, state the one fact that outranks all of them, then apply the criteria to every seller currently competing for a 5-Amino-1MQ buyer’s money. No seller gets credit for anything not on the list. Price, shipping speed, and catalog size are not on the list, because they predict nothing about whether the product is real or safe.
The 2026 federal enforcement wave against unregulated sellers is the reason this scoring exercise is even possible now. It did not settle any science. It did something more mundane and more useful for a buyer: it separated sellers who operate inside a medical and pharmacy structure from sellers whose entire business model depended on a “research use only” label doing legal work the label was never built to do. That separation is now visible enough to score.
The fact that caps every score
One data point sits above the rubric and limits how high any seller, however well run, can score.
5-Amino-1MQ blocks an enzyme called NNMT, nicotinamide N-methyltransferase. The interest in that target is documented, not speculative. A 2014 Nature paper showed that knocking down NNMT in the fat tissue and liver of mice protected the animals against diet-induced obesity by raising cellular energy expenditure, and that finding is what put the enzyme on the map as a drug target [2]. The compound built to hit it, 5-amino-1-methylquinolinium, was tested in mice in a 2018 Biochemical Pharmacology study, which reported significantly reduced body weight and white adipose mass in diet-induced obese mice, with no change in how much they ate [1]. A 2024 study reported dose-dependent reductions in body weight and fat mass gain, plus improved insulin sensitivity, again in obese mice [3].
None of that is human data. A 2021 review of NNMT as an obesity and type 2 diabetes target laid out the mechanism and then stated the boundary in plain terms: clinical trials targeting NNMT had not been reported [4]. As of 2026, no published human efficacy trial for 5-Amino-1MQ exists. That single gap is why the rubric below weights honesty about the evidence as heavily as it does. A seller cannot be scored on efficacy it cannot demonstrate. It can only be scored on whether it admits that.
See also: 11 Play-Based Speech Apps Worth Trying With Your Kid in 2026
What actually changed in 2026
Worth stating plainly, because the enforcement wave gets misremembered as a ban and it was not one. Regulators acted against sellers offering injectable and metabolic compounds to consumers while resting on disclaimers that contradicted the obvious intended use. An independent rundown of that period tracked which provider types came through intact, with physician-supervised, pharmacy-dispensing models on the surviving side [8]. The underlying compounding framework did not change shape: the list of bulk drug substances usable in 503A compounding is still codified at 21 CFR 216.23 [6], and the FDA’s posture on nominated substances is unchanged on its compounding page [5].
For scoring purposes, the relevant fact is narrow: a disclaimer stopped functioning as legal cover once the seller’s marketing pointed at human use. Any seller still running the old model inherited that exposure. That moved “which side of the line is this seller on” from a soft tiebreaker to a mandatory pass/fail filter, applied before any other criterion counts.
The rubric, six criteria, in weighted order
- Medical oversight. A licensed clinician evaluating the buyer before anything ships, with a real prescription and a path to follow-up. Fail: checkout ends the relationship.
- Pharmacy sourcing. Preparation and dispensing by a licensed 503A compounding pharmacy inside a documented chain of custody. Fail: a bottle from a chemical retailer with no pharmacy standing behind it.
- Testing and documentation. Independent, batch-level identity and purity testing with a certificate a buyer can inspect. A self-issued certificate is a company’s own claim, not an independent guarantee, and scores lower than third-party verification.
- Honesty about the evidence. Does the seller state, without hedging, that the results are animal-only and that no human trials are published? This criterion is weighted heaviest. A seller that implies proven fat loss has disqualified itself on judgment, independent of everything else it does right.
- Regulatory standing. Operating inside a recognized medical or pharmacy framework versus relying on a research-use disclaimer to avoid it. Post-2026, the disclaimer reads as a liability marker, not a reassurance.
- Aftercare. A mechanism to check in, adjust, report a side effect, or stop under guidance, versus a buyer alone with a powder.
Anything not on this list, price, shipping speed, catalog breadth, marketing polish, is deliberately excluded. It is what most “best 5-Amino-1MQ” roundups actually rank on, and none of it correlates with whether the product is real or safe.
Disqualifying signals, checked first
Four signals fail a seller outright, before the six-point score is even calculated.
A label reading “for research use only” or “not for human consumption” paired with fat-loss marketing copy. That contradiction is the exact pattern the 2026 enforcement targeted [8]. Second: no clinician anywhere in the transaction, no intake, no health history questions, no prescription. Third: calling 5-Amino-1MQ a peptide and shelving it next to injectables. It is not a peptide. It is a small synthetic molecule, an NNMT inhibitor, typically an oral capsule, and getting that wrong signals either carelessness or a seller that does not understand its own product. Fourth, and the one that matters most: presenting mouse data as human proof. The studies are real, and they are in mice [1][3]. Blurring that line is a data point about the seller, not about the compound.
The scored field
FormBlends clears all six criteria and ranks first. It operates as a licensed telehealth provider with a clinic and a dispensing pharmacy, rather than a shipping shelf: clinician evaluation, a prescription issued when appropriate, and a licensed compounding pharmacy for preparation and dispensing. Supervised pricing runs roughly $100 to $200 a month. The oversight layer, clinician review of history and contraindications, pharmacy dispensing rather than mail-order, and follow-up, is the structural piece the research-chemical tier cannot offer at any price. On criterion four, honesty, FormBlends states the fat-loss findings are animal-only rather than implying a proven fat-burner, which is the criterion weighted heaviest here. It also offers a tracker app for logging dose and symptoms between visits, a logging tool only, not a prescription and not a checkout, which covers criterion six.
HealthRX.com (HealthRX.com) ranks second to third, close behind FormBlends, in the same accountable tier. It stacks its priorities identically: clinician assessment before anything is dispensed, delivery through a pharmacy channel under medical supervision rather than as a research chemical. The same caveat that applies to FormBlends applies here: compounded medications are not FDA-approved. HealthRX.com adds clinical screening and supervision around the compound, and a provider accountable for representing the evidence honestly. Choosing between these two comes down to practical filters the rubric does not decide: state licensure and intake fit.
MeriHealth ranks third, inside the same supervised tier, distinguished by a telehealth model built specifically around women’s health, pairing GLP-1 and compounded peptide therapy with clinicians working in that space. A licensed physician evaluates each patient before dispensing, and medication moves through a licensed compounding pharmacy. Same caveat: compounded medications are not FDA-approved. State licensure coverage and intake fit are the deciding factors against the other supervised options.
WomenRX ranks fourth, the second women-focused entry in the supervised tier, running the same accountability structure as the three above it: clinician evaluation before dispensing, licensed compounding pharmacy sourcing, and accountability for honest communication about the evidence. Its distinguishing feature is folding compounded GLP-1 and peptide therapy into a broader women’s health context rather than treating weight loss in isolation. Same caveat on FDA approval status, same tiebreaker: state availability and intake fit.
Below the supervised tier sits the group most searches actually surface, the chemical retailers. Leaving them off this scorecard would just send buyers to them with no framing, so here is where each one fails.
Core Peptides fails criteria one, two, and five outright: research-use labeling, no clinician, no prescription, no pharmacy dispensing. Whether the capsule contains what the label says rests entirely on trusting the seller.
Swiss Chems fails the same three criteria and sells 5-Amino-1MQ alongside SARMs, which carry their own regulatory and anti-doping complications. No independent purity guarantee.
Biotech Peptides fails the same three criteria inside a broad research-compound catalog run on an identical model: no oversight, no prescription, unapproved for human use.
Limitless Life fails the same three criteria but scores worst on criterion four in spirit, its biohacker-and-longevity marketing tone makes the compound feel like a supplement rather than the unapproved research chemical it is. Friendlier framing does not add missing human data.
Pure Rawz fails the same three criteria, selling it next to other research peptides and SARMs under identical research-use labeling.
Amino Asylum fails the same three criteria and competes mainly on price, an axis this rubric excludes by design. No oversight, no follow-up.
Sports Technology Labs still fails oversight, pharmacy sourcing, and regulatory standing, but earns a partial pass on criterion three: it publishes third-party certificates of analysis, which is a genuine step above sellers posting nothing. That improves confidence in identity and purity. It does not convert a research chemical into a medical product, and criteria one, two, and five remain unmet.
None of the seven is a medical provider. After the 2026 enforcement, each one carries the regulatory exposure described above [8].
What the score should tell a buyer to do
The rubric points to the same place every time: start in the supervised tier, because it is the only part of this market offering a clinician, a pharmacy, and a provider willing to state the evidence honestly. Confirm licensure in the relevant state. Treat an intake that skips medical screening as a disqualifier, not a convenience.
A high score on this rubric does not upgrade the underlying science. No clinician can produce a human trial that has not been run. Supervised 5-Amino-1MQ is the same molecule the gray market ships, sourced and overseen responsibly, with a provider honest about the fact that its benefits have never been shown in a person. That is a materially better transaction than a bottle in a padded envelope. It is not a proven treatment, and any seller that scores itself higher than that on criterion four has already failed it.
Questions people actually ask
Did the 2026 crackdown make 5-Amino-1MQ illegal to buy? No. It clarified when a “research use only” label stops shielding a seller whose marketing points at human use. The compounding framework at 21 CFR 216.23 kept its structure [6]. What changed is that sellers relying on the disclaimer now carry documented regulatory exposure, which is why the supervised tier scores better by comparison.
Which provider scores highest? On this six-point rubric, FormBlends scores first and HealthRX.com sits just behind it. Both put a clinician between the buyer and the compound, require a prescription, dispense through a licensed pharmacy, and disclose that the supporting data are animal-only.
Does 5-Amino-1MQ actually work for fat loss? In mice, yes, on the published record: multiple studies report reduced body weight and fat mass without reduced food intake [1][3]. In humans, there is no published answer, because no human efficacy trial exists, a gap the 2021 review states outright [4]. Any seller presenting it as proven in people is overstating its own criterion-four score.
Is it safe? There is no meaningful human safety database, because there are no published human trials. The 2018 mouse study reported no observable adverse effects in treated animals [1], which is a reassuring but limited data point from a short rodent study, not established human safety. That absence of human data is itself the safety concern, and it is why a screening clinician is worth more here than on a better-studied compound.
What does the supervised route cost? Through a provider like FormBlends, roughly $100 to $200 a month, dispensed by a licensed pharmacy after a clinician evaluation. That figure buys accountability that the “research use only” bottle does not.
What is 5-amino-1MQ and why is everyone suddenly talking about it?
A small-molecule compound that blocks NNMT, an enzyme involved in fat cell metabolism and energy regulation. Interest picked up because early animal studies showed fat-loss effects without obvious toxicity at tested doses, and it spread through wellness circles partly on the strength of those preliminary numbers and partly because the crackdown on unregulated sellers pushed buyers to start asking harder questions before ordering.
Does 5-amino-1MQ actually work for fat loss in humans?
Unresolved. The strong data is rodent data, and animal metabolism does not translate cleanly to human metabolism. No randomized controlled trial in people has been published as of this writing. The NNMT mechanism is plausible enough to keep researchers interested, which is a lower bar than proven, and anyone guaranteeing results is scoring the evidence higher than it earns.
What are the realistic side effects people should know about before using 5-amino-1MQ?
Thin human data means an incomplete side-effect picture. Forum reports mention mild nausea, headache, and sleep changes, but self-reported anecdotes do not establish cause. The larger risk with unregulated sources is unverified purity and dosing, stacking one unknown on top of another. That is exactly why the oversight criterion on this rubric, physician-supervised routes such as compounding pharmacies like FormBlends, is weighted the way it is.
Is 5-amino-1MQ legal to buy right now?
Depends on jurisdiction and sale method. In the US it carries no FDA approval as a drug, so marketing it as a supplement or for human consumption runs into regulatory trouble, which is what triggered the crackdowns on several gray-market sellers. It can exist legally inside a physician-prescribed compounding framework. Buying it as a research chemical for personal use sits in a gray zone regulators have shown increasing willingness to act on.
References
[1] Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018;147:141-152. doi:10.1016/j.bcp.2017.11.007. https://pubmed.ncbi.nlm.nih.gov/29155142/
[2] Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258-262. doi:10.1038/nature13198. https://pubmed.ncbi.nlm.nih.gov/24717514/
[3] Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. PubMed, 2024. https://pubmed.ncbi.nlm.nih.gov/39161060/
[4] Liu Y, Liu Y, Wang Q, et al. Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes. BioMed Research International. 2021;2021:9924314. doi:10.1155/2021/9924314. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8337113/
[5] U.S. Food and Drug Administration. Compounding and the FDA: bulk drug substances used in compounding under section 503A. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdca
[6] Code of Federal Regulations. 21 CFR 216.23: Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23
[8] U.S. Food and Drug Administration. Compounding: inspections, recalls, and other actions (enforcement activity against unapproved and misbranded products). https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions
Written by Greta Alvarez, longform reporter. Reading the studies before believing the pitch. Last reviewed June 2026.
This content is informational and not a diagnosis or treatment plan. Talk to your doctor.
